2024 SABCS Meeting Magazine - A2

New Data for Gene Expression Tests
Focused Medical Discussions
VERACYTE BOOTH #1243
WEDNESDAY, DECEMBER 11
12:30 PM ALTERNATE data and preop endocrine therapy
Prof. Matthew Ellis, Houston, Texas
1:00 PM OPTIMA - Trials updates
Prof. Rob Stein, University College London
3:00 PM
Prosigna's impact on risk stratification in HR+/HER2- EBC:
a real-world comparison with OncotypeDX
Dr. Nicola Fusco and Dr. Giulia Cursano, IEO, Milan
5:30 PM How is Prosigna utilised in the United Kingdom?
Findings from a multi-centre RWE study
Dr. Thiraviyam Elumalai, Cambridge University
Schedule
available
online
THURSDAY, DECEMBER 12
12:30 PM Intrinsic subtype at progression to CDK4/6 inhibitors plus endocrine
therapy in HR+/HER2- metastatic breast cancer
Dr. Francesco Schettini, Hospital Clinic, Barcelona
1:00 PM Experience with Prosigna assay from a tertiary hospital in Spain
Dr. Rodrigo Sánchez Bayona, Hospital 12 de octubre, Madrid
1:30 PM Performance of Genomic Assays in Diverse Populations
Prof. Melissa Troester, Carolina Breast Cancer Study, University North Carolina
3:00 PM
5:30 PM
Unlocking the potential of Prosigna-based trial designs in
personalized breast cancer therapeutics
Dr. Tomás Pascual, Hospital Clinic, Barcelona
Retrospective Analysis of different gene expression tests in
HR+/HER2- breast cancer: correlation of Prosigna with EndoPredict
and MammaPrint
Brigitte Schober, Feldkirch, Austria
MKTG_PRSGN_ADV_101124_041_01
https://www.prosigna.com/
2024 SABCS Meeting Magazine

Table of Contents for the Digital Edition of 2024 SABCS Meeting Magazine
